Epigenetics and chronic lymphocytic leukemia

American Journal of Hematology

Volumn 81, Issue 11, 2006, Pages 864-869

  Yu, Margaret K ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Chronic lymphocytic leukemia; DNA methylation; Hypomethylation; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR;

CHRONIC LYMPHATIC LEUKEMIA; CORRELATION ANALYSIS; DEMETHYLATION; DNA METHYLATION; DNA SYNTHESIS INHIBITION; DRUG STRUCTURE; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

DINUCLEOSIDE PHOSPHATES; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MODELS, MOLECULAR; PROMOTER REGIONS (GENETICS);

EID: 33750585379     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20718     Document Type: Short Survey

References (67)

1. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 2004;13:279-287.
2. Dai MS, Chang H, Peng MY, Ho CL, Chao TY. Suppurative Salmonella thyroiditis in a patient with chronic lymphocytic leukemia. Ann Hematol 2003;82:646-648.
3. Levidiotou S, Charalabopoulos K, Vrioni G, et al. Fatal meningitis due to Listeria monocytogenes in elderly patients with underlying malignancy. Int J Clin Pract 2004;58:292-296.
4. Machado Od Ode O, Goncalves R, Fernandes EM, Campos WR, Orefice F, Curi AL. Bilateral Aspergillus endophthalmitis in a patient with chronic lymphocytic leukaemia. Br J Ophthalmol 2003;87:1429-1430.
5. Robinson H, Smith S. Mycobacterium fortuitum infection in a patient with chronic lymphocytic leukaemia. Br J Haematol 2004; 127:126.
6. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:1947-1950.
7. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
8. Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OK, Oscier D. Zap-70 methylation status is associated with Zap-70 expression status in chronic lymphocytic leukemia. Haematologica 2005;90:1078-1088.
9. Rai KR, Dohner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: Case-based session. Hematology (Am Soc Hematol Educ Program) 2001:140-156.
10. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004:163-183.
11. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002;16:985-992.
12. Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. Annu Rev Genomics Hum Genet 2004;5:479-510.
13. Liu L, Lai S, Andrews LG, Tollefsbol TO. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 2004;340:1-10.
14. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-586.
15. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 1998;17:4905-4608.
16. Shen JC, Rideout WM III, Jones PA. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res 1994;22:972-976.
17. Rideout WM III, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990;249:1288-1290.
18. Stach D, Schmitz OJ, Stilgenbauer S, et al. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003;31:E2.
19. Lyko F, Stach D, Brenner A, et al. Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. Electrophoresis 2004;25:1530-1535.
20. Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Janne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992;80:2074-2080.
21. Belinsky SA, Nikula KJ, Baylin SB, Issa JP. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA 1996;93:4045-4050.
22. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003;9:4415-4422.
23. Nass SJ, Ferguson AT, El-Ashry D, Nelson WG, Davidson NE. Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. Oncogene 1999;18:7453-7461.
24. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res 2000;28:2108-2113.
25. Nakagawa T, Kanai Y, Saito Y, Kitamura T, Kakizoe T, Hirohashi S. Increased DNA methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder. J Urol 2003;170:2463-2466.
26. Jin F, Dowdy SC, Xiong Y, Eberhardt NL, Podratz KC, Jiang SW. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecol Oncol 2005;96:531-538.
27. Robertson KD, Jones PA. DNA methylation: Past, present and future directions. Carcinogenesis 2000;21:461-467.
28. Fuke C, Shimabukuro M, Petronis A, et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: An HPLC-based study. Ann Hum Genet 2004;68:196-204.
29. Wilson VL, Smith RA, Ma S, Cutler RG. Genomic 5-methyldeoxycytidine decreases with age. J Biol Chem 1987;262:9948-9951.
30. Ross SA. Diet and DNA methylation interactions in cancer prevention. Ann N Y Acad Sci 2003;983:197-207.
31. Pogribny I, Raiche J, Slovack M, Kovalchuk O. Dose-dependence, sex- and tissue-specificity, and persistence of radiation-induced genomic DNA methylation changes. Biochem Biophys Res Commun 2004;320:1253-1261.
32. D'Arena G, Di Renzo N, Brugiatelli M, Vigliotti ML, Keating MJ. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2003;44:223-228.
33. Kn H, Bassal S, Tikellis C, El-Osta A. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-Cell and B-Cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther 2004;3:989-994.
34. Sato M, Horio Y, Sekido Y. Minna JD, Shimokata K, Hasegawa Y. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene 2002;21:4822-4829.
35. Szyf M, Detich N. Regulation of the DNA methylation machinery and its role in cellular transformation. Prog Nucleic Acid Res Mol Biol 2001;69:47-79.
36. Rhee I, Jair KW, Yen RW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 2000;404:1003-1007.
37. Ting AH, Jair KW, Suzuki H, Yen RW, Baylin SB, Schuebel KE. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet 2004;36:582-584.
38. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-1819.
39. Lubbert M. Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: An early or later epigenetic alteration in myelodysplastic syndromes? Leukemia 2003;17:1762-1764.
40. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003;17:910-918.
41. Au WY, Fung A, Man C, et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: Clinicopathological and karyotypic associations. Br J Haematol 2003;120:1062-1065.
42. Aoki E, Uchida T, Ohashi H, et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000;14: 586-593.
43. Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma 1999;35:437-443.
44. Preisler HD, Li B, Chen H, et al. P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. Leukemia 2001;15:1589-1595.
45. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-2964.
46. Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004;64:2424-2433.
47. Raval A, Lucas DM, Matkovic JJ, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005;23:3877-3885.
48. Takahashi T, Shivapurkar N, Reddy J, et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10:2928-2935.
49. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
50. Hammarsund M, Corcoran MM, Wilson W, et al. Characterization of a novel B-CLL candidate gene- DLEU7-located in the 13q14 tumor suppressor locus. FEBS Lett 2004;556:75-80.
51. Liu Y, Szekely L, Grander D, et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 1993;90:8697-8701.
52. Bezieau S, Devilder MC, Rondeau G, Cadoret E, Moisan JP, Moreau I. Assignment of 48 ESTs to chromosome 13 band q14.3 and expression pattern for ESTs located in the core region deleted in B-CLL. Genomics 1998;52:369-373.
53. Mabuchi H, Fujii H, Calin G, et al. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res 2001;61:2870-2877.
54. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
55. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-191.
56. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003;Suppl. 3:245-254.
57. Klein RR, Houtz RL. Cloning and developmental expression of pea ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit N-methyltransferase. Plant Mol Biol 1995;27:249-261.
58. Esteller M. DNA methylation and cancer therapy: New developments and expectations. Curr Opin Oncol 2005;17:55-60.
59. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
60. Teofili L, Martini M, Di Mario A, et al. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 2001;98: 495-497.
61. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-5495.
62. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984;81:6993-6997.
63. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-11801.
64. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE: Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 1997;272:32260-32266.
65. Gowher H, Jeltsch A. Mechanism of inhibition of DNA methyltransfers by cytidine analogs in cancer therapy. Cancer Biol Ther 2004;3:1062-1068.
66. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640.
67. Austen B. Fegan C, Moss P, Stankovic T. ATM mutations define a subset of B-CLL tumors that only partially correlates with 11q status and is associated with impaired patient survival. Blood 2004;104:221a-222a Abstract 774.